Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > Manhattan Scientifics Acquires Exclusive Rights to Nanomedicine Technology for Early Cancer Detection and Treatment

Abstract:
Ground-Breaking Technology Developed by Dr. Edward R. Flynn Requires No Radiation and is 100x More Sensitive Than Existing Diagnostics; Techniques Enable Early Cancer Detection and Precise, Image Guided Cancer Therapies

Manhattan Scientifics Acquires Exclusive Rights to Nanomedicine Technology for Early Cancer Detection and Treatment

Albuquerque, NM | Posted on February 25th, 2010

Manhattan Scientifics Inc. (OTCBB: MHTX), a nanomedicine technology transfer and commercialization pioneer, today announced completion of its agreement to acquire all commercial rights to the body of work of nuclear physicist Edward R. Flynn, PhD and his company, Senior Scientific LLC. The breakthrough technology focuses on the emerging field of nanomedicine, with an emphasis on the early detection and localization of cancer and other diseases, and providing image-guided therapy for treatment. Financial details of the agreement were not disclosed.

Early detection of cancer can be critical to effective treatment. For example, current mammography cannot detect a breast cancer tumor until it has grown to over ten million cells. Dr. Flynn's technology has proven the ability to detect breast cancer tumors while they are only 1% that large, resulting in a hundred-fold increase in sensitivity and early detection. The new technology has demonstrated similar performance in detecting ovarian cancer, a cancer with no effective screening techniques. It has also demonstrated effectiveness in monitoring chemotherapy for leukemia, allowing more effective treatment with fewer side effects. Dr. Flynn's work has been supported for eight years by 9 grants from the National Institutes of Health and one from the U.S. Department of Defense. The technology is protected by issued and pending patents.

Dr. Flynn explains, "Our approach uses sophisticated magnetic field sensors to measure extremely small magnetic fields emitted by magnetic nanoparticles that have been injected into the body and targeted specifically toward cancer cells. This method yields high contrast images of tumors compared to normal cells. With this biomagnetic imaging technique, it is possible to identify and image small clusters of cancer cells, providing the ability to find cancer at a substantially earlier stage than is presently possible. This technology has a distinct advantage over other imaging methods in that it detects only particles bound to targeted cells and is not sensitive to unbound particles where other methods may be overwhelmed by the unbound particles. It is done without the use of ionizing radiation. This biomagnetic sensor method is applicable to breast, ovarian, leukemia, prostate, and potentially to many other cancers."

"Over the last four years in serving as science advisor to Governor Richardson, I have seen numerous technologies being developed in New Mexico. Only two have stood out as truly revolutionary. Of those two, the effort by Ed Flynn and his group is the one that is poised to have the greatest impact on the human condition. This is a great example of the kind of progress that is possible when a highly talented scientist takes an interdisciplinary approach to solving a critical health challenge," said Thomas J. Bowles, who previously served as the Chief Science Officer of Los Alamos National Laboratory, where he had oversight of $100 million annually in discretionary research funds and interfaced with other R&D institutions.

Manny Tsoupanarias, CEO of Manhattan Scientifics, commented, "Following the path of our established business model, we intend to work in close cooperation with pharmaceutical companies and world-class medical device manufacturers to bring this technology to the global market. We are currently defining initial business opportunities for the technology, and we are exploring strategic relationships with companies possessing the expertise, marketing skills, and capital to bring product to market under royalty bearing agreements. The Company has demonstrated its ability to ‘partner' with a Fortune 1000 industrial company, Carpenter Technology Corporation (NYSE: CRS), in another of its nano technology developments, producing revenue and earnings for Manhattan Scientifics."

"I've helped build companies in the past with hundreds of millions of dollars of value created for shareholders in high technology areas, but have never before been so excited about a medical advancement with such profound implications for humanity," said Marvin Maslow, former Chairman of Manhattan Scientifics and currently its leading commercialization consultant.

This press release contains forward-looking statements. Such forward-looking statements are subject to a number of risks, assumptions and uncertainties that could cause the Company's actual results to differ materially from those projected in such forward-looking statements. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly update or revise any forward-looking statements.

####

About Manhattan Scientifics
Manhattan Scientifics Inc. (OTCBB: MHTX) is a pioneer in the field of nanomedicine technology transfer and commercialization. Focused on disruptive technologies for diagnostic, therapeutic and prosthetic purposes, Manhattan Scientifics is presently developing commercial medical prosthetics applications for its ultra fine grain metals, and plans to commercialize the cancer research work developed by Edward R. Flynn, PhD and Senior Scientific, LLC. The company is located in New Mexico, New York and Montreal. Additional information is available at www.mhtx.com.

For more information, please click here

Contacts:
Manhattan Scientifics, Inc.
Marvin Maslow
917-923-3300

Copyright © Manhattan Scientifics

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Pixelligent Launches New PixClear® Light Extraction Materials for OLED Lighting August 4th, 2015

The annual meeting on High Power Diode Lasers & Systems will be held as part of the Enlighten Conference, October 14th & 15th August 4th, 2015

Atomic view of microtubules: Berkeley Lab researchers achieve record 3.5 angstroms resolution and visualize action of a major microtubule-regulating protein August 4th, 2015

World's quietest gas lets physicists hear faint quantum effects August 4th, 2015

Nanomedicine

Atomic view of microtubules: Berkeley Lab researchers achieve record 3.5 angstroms resolution and visualize action of a major microtubule-regulating protein August 4th, 2015

Artificial blood vessels become resistant to thrombosis August 4th, 2015

Nanoparticles used to breach mucus barrier in lungs: Proof-of-concept study conducted in mice a key step toward better treatments for lung diseases August 3rd, 2015

Promising Step Taken in Iran towards Treatment of Spinal Cord Injury August 3rd, 2015

Announcements

Artificial blood vessels become resistant to thrombosis August 4th, 2015

Engineering a better 'Do: Purdue researchers are learning how August 4th, 2015

Proving nanoparticles in sunscreen products August 4th, 2015

Global Carbon Nanotubes Industry 2015: Acute Market Reports August 4th, 2015

Patents/IP/Tech Transfer/Licensing

Quantum networks: Back and forth are not equal distances! July 28th, 2015

Reshaping the solar spectrum to turn light to electricity: UC Riverside researchers find a way to use the infrared region of the sun's spectrum to make solar cells more efficient July 27th, 2015

Smarter window materials can control light and energy July 22nd, 2015

Magnetic nanoparticles could be key to effective immunotherapy: New method moves promising strategy closer to clinical use July 15th, 2015

Nanobiotechnology

Atomic view of microtubules: Berkeley Lab researchers achieve record 3.5 angstroms resolution and visualize action of a major microtubule-regulating protein August 4th, 2015

Heating and cooling with light leads to ultrafast DNA diagnostics July 31st, 2015

European Technology Platform for Nanomedicine and ENATRANS European Consortium Launch the 2nd edition of the Nanomedicine Award: The Award to be presented at BIO-Europe conference in Munich, November 2015 July 30th, 2015

New computer model could explain how simple molecules took first step toward life: Two Brookhaven researchers developed theoretical model to explain the origins of self-replicating molecules July 28th, 2015

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project